vs
ANI PHARMACEUTICALS INC（ANIP）とPROGRESS SOFTWARE CORP（PRGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
PROGRESS SOFTWARE CORPの直近四半期売上が大きい（$252.7M vs $247.1M、ANI PHARMACEUTICALS INCの約1.0倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 10.2%、差は0.9%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 17.5%）。PROGRESS SOFTWARE CORPの直近四半期フリーキャッシュフローが多い（$59.9M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 17.0%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
プログレスソフトウェアコーポレーションは、アプリケーション開発プラットフォーム、データ接続ツール、デジタルエクスペリエンスソリューションなどの企業向けソフトウェアを開発・販売しています。金融、医療、製造、小売など世界中の多様な業界の顧客にサービスを提供し、業務効率化と高性能業務アプリの構築を支援しています。
ANIP vs PRGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $252.7M |
| 純利益 | $27.5M | $25.7M |
| 粗利率 | — | 81.6% |
| 営業利益率 | 14.1% | 15.2% |
| 純利益率 | 11.1% | 10.2% |
| 売上前年比 | 29.6% | 17.5% |
| 純利益前年比 | 367.5% | 2144.6% |
| EPS（希薄化後） | $1.14 | $0.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $252.7M | ||
| Q3 25 | $227.8M | $249.8M | ||
| Q2 25 | $211.4M | $237.4M | ||
| Q1 25 | $197.1M | $238.0M | ||
| Q4 24 | $190.6M | $215.0M | ||
| Q3 24 | $148.3M | $178.7M | ||
| Q2 24 | $138.0M | $175.1M | ||
| Q1 24 | $137.4M | $184.7M |
| Q4 25 | $27.5M | $25.7M | ||
| Q3 25 | $26.6M | $19.4M | ||
| Q2 25 | $8.5M | $17.0M | ||
| Q1 25 | $15.7M | $10.9M | ||
| Q4 24 | $-10.3M | $1.1M | ||
| Q3 24 | $-24.2M | $28.5M | ||
| Q2 24 | $-2.3M | $16.2M | ||
| Q1 24 | $18.2M | $22.6M |
| Q4 25 | — | 81.6% | ||
| Q3 25 | — | 81.0% | ||
| Q2 25 | — | 80.1% | ||
| Q1 25 | — | 80.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 83.7% | ||
| Q2 24 | — | 81.7% | ||
| Q1 24 | — | 82.2% |
| Q4 25 | 14.1% | 15.2% | ||
| Q3 25 | 15.9% | 17.6% | ||
| Q2 25 | 6.6% | 16.3% | ||
| Q1 25 | 13.3% | 13.6% | ||
| Q4 24 | -2.3% | 10.0% | ||
| Q3 24 | -13.8% | 22.6% | ||
| Q2 24 | 3.7% | 15.5% | ||
| Q1 24 | 14.8% | 19.0% |
| Q4 25 | 11.1% | 10.2% | ||
| Q3 25 | 11.7% | 7.8% | ||
| Q2 25 | 4.0% | 7.2% | ||
| Q1 25 | 8.0% | 4.6% | ||
| Q4 24 | -5.4% | 0.5% | ||
| Q3 24 | -16.3% | 15.9% | ||
| Q2 24 | -1.7% | 9.2% | ||
| Q1 24 | 13.2% | 12.3% |
| Q4 25 | $1.14 | $0.59 | ||
| Q3 25 | $1.13 | $0.44 | ||
| Q2 25 | $0.36 | $0.39 | ||
| Q1 25 | $0.69 | $0.24 | ||
| Q4 24 | $-0.45 | $0.01 | ||
| Q3 24 | $-1.27 | $0.65 | ||
| Q2 24 | $-0.14 | $0.37 | ||
| Q1 24 | $0.82 | $0.51 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $94.8M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $540.7M | $478.3M |
| 総資産 | $1.4B | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 2.93× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $94.8M | ||
| Q3 25 | $262.6M | $99.0M | ||
| Q2 25 | $217.8M | $102.0M | ||
| Q1 25 | $149.8M | $124.2M | ||
| Q4 24 | $144.9M | $118.1M | ||
| Q3 24 | $145.0M | $232.7M | ||
| Q2 24 | $240.1M | $190.4M | ||
| Q1 24 | $228.6M | $133.2M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $478.3M | ||
| Q3 25 | $505.8M | $477.7M | ||
| Q2 25 | $436.8M | $452.7M | ||
| Q1 25 | $418.6M | $431.8M | ||
| Q4 24 | $403.7M | $438.8M | ||
| Q3 24 | $405.9M | $425.6M | ||
| Q2 24 | $455.8M | $401.7M | ||
| Q1 24 | $452.0M | $461.7M |
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.4B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.6B | ||
| Q1 24 | $914.5M | $1.5B |
| Q4 25 | — | 2.93× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 3.22× | ||
| Q1 25 | — | 3.50× | ||
| Q4 24 | — | 3.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $62.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $59.9M |
| FCFマージンFCF / 売上 | 11.8% | 23.7% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.44× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $229.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $62.8M | ||
| Q3 25 | $44.1M | $73.4M | ||
| Q2 25 | $75.8M | $30.0M | ||
| Q1 25 | $35.0M | $68.9M | ||
| Q4 24 | $15.9M | $19.7M | ||
| Q3 24 | $12.5M | $57.7M | ||
| Q2 24 | $17.4M | $63.7M | ||
| Q1 24 | $18.3M | $70.5M |
| Q4 25 | $29.1M | $59.9M | ||
| Q3 25 | $38.0M | $72.4M | ||
| Q2 25 | $71.8M | $29.5M | ||
| Q1 25 | $32.5M | $67.7M | ||
| Q4 24 | $13.5M | $16.8M | ||
| Q3 24 | $7.7M | $56.6M | ||
| Q2 24 | $13.0M | $62.7M | ||
| Q1 24 | $13.7M | $70.2M |
| Q4 25 | 11.8% | 23.7% | ||
| Q3 25 | 16.7% | 29.0% | ||
| Q2 25 | 34.0% | 12.4% | ||
| Q1 25 | 16.5% | 28.4% | ||
| Q4 24 | 7.1% | 7.8% | ||
| Q3 24 | 5.2% | 31.7% | ||
| Q2 24 | 9.4% | 35.8% | ||
| Q1 24 | 10.0% | 38.0% |
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 0.4% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 1.3% | ||
| Q3 24 | 3.2% | 0.6% | ||
| Q2 24 | 3.2% | 0.5% | ||
| Q1 24 | 3.3% | 0.2% |
| Q4 25 | 1.10× | 2.44× | ||
| Q3 25 | 1.66× | 3.78× | ||
| Q2 25 | 8.87× | 1.76× | ||
| Q1 25 | 2.23× | 6.30× | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 3.93× | ||
| Q1 24 | 1.00× | 3.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
